Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation
Abstract Blinatumomab, a CD19/CD3 bispecific T-cell engager, is frequently used for B-cell acute lymphoblastic leukemia (B-ALL) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although its efficacy in achieving measurable residual disease negativity is well established, its...
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Springer
2026-01-01
|
| Серія: | Annals of Hematology |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1007/s00277-026-06738-2 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|